|Patient Safety Information and Resources|
The Spine Intervention Society is committed to assisting spine care providers in delivering the safest care possible for patients. To this end, we monitor multiple government sources to identify issues of relevance to interventional spine care providers and patients. Additional links and information that may be of assistance are included below.
Centers for Disease Control and Prevention: www.cdc.gov
CDC's One & Only Campaign
We are proud to announce that the Spine Intervention Society has recently become a member of the One & Only Campaign, a public safety campaign to promote safe injection practices in all healthcare settings. By teaming up with the Safe Injection Practices Coalition, we're joining professional groups, healthcare systems, provider groups, private companies and others dedicated to raising awareness of the importance of injection safety. Click here to learn more and download materials.
Injection Safety: www.cdc.gov/injectionsafety
Safe Injection Practices are a set of recommendations within Standard Precautions, which are the foundation for preventing transmission of infections during patient care in all healthcare settings including hospitals, long-term care facilities, ambulatory care, home care and hospice. The most recent guideline outlining Standard Precautions is the Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Healthcare Settings 2007
CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016
Deborah Dowell, MD; Tamara M. Haegerich, PhD; Roger Chou, MD.
This guideline provides recommendations for primary care providers who are prescribing opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care. The guideline addresses 1) when to initiate or continue opioids for chronic pain; 2) opioid selection, dosage, duration, follow-up, and discontinuation; and 3) assessing risk and addressing harms of opioid use. This guideline is intended to improve communication between providers and patients about the risks and benefits of opioid therapy for chronic pain, improve the safety and effectiveness of pain treatment, and reduce the risks associated with long-term opioid therapy, including abuse, dependence, overdose, and death.
Food and Drug Administration: www.fda.gov
Health Care Professionals: www.fda.gov/ForHealthProfessionals/default.htm
Know Your Source: http://www.fda.gov/Drugs/ResourcesForYou/HealthProfessionals/ucm389121.htm
On March 24, 2016, the U.S. Food and Drug Administration issued a draft guidance intended to support industry in their development of generic versions of approved opioids with abuse-deterrent formulations (ADF) while ensuring that generic ADF opioids are no less abuse-deterrent than the brand-name drug. Today’s actions are among a number of steps the agency recently outlined in an action plan to reassess its approach to opioid medications. The plan is focused on policies aimed at reversing the epidemic, while still providing patients in pain access to effective relief.
For more information, please visit: abuse- deterrent opioids.
In response to the opioid abuse epidemic, on February 4, 2016, Dr. Robert Califf, the FDA’s Deputy Commissioner for Medical Products and Tobacco, along with other FDA leaders, called for a far-reaching action plan to reassess the agency’s approach to opioid medications. The plan aims at reversing the epidemic, while still providing patients in pain access to effective relief.
As one of the cornerstones of this plan, the FDA will seek guidance from outside experts in the fields of pain management and drug abuse. For example, the FDA has already asked the National Academy of Medicine to help develop a framework for opioid review, approval, and monitoring that balances individual need for pain control with considerations of the broader public health consequences of opioid misuse and abuse.
AMA Task Force to Reduce Opioid Abuse
The American Medical Association has formed the AMA Task Force to Reduce Opioid Abuse to help coordinate, develop, and implement specific recommendations to ensure effective pain management practices and evidence-based prescribing of opioids; promote appropriate referrals and access to care for patients with opioid use disorders; and take necessary steps needed to reduce opioid-related harm. The Task Force has launched a web-based resource (www.ama-assn.org/go/endopioidabuse) and will soon begin a national ad campaign to increase physicians’ registration and use of prescription drug monitoring programs as well as promote enhanced education and training to ensure that physicians take the lead in becoming educated about evidence-based care and appropriate prescribing practices. The new website offers courses and educational materials offered by the American Osteopathic Association, American Dental Association, 55 state and specialty medical societies, and other key stakeholders. Resources include:
3/10/2017 » 3/12/2017
Advanced Lumbar Bio-Skills Lab - Tampa, FL
3/11/2017 » 3/12/2017
European Lumbar Bio-Skills Lab - Amsterdam, NL
4/21/2017 » 4/23/2017
Cervical Bio-Skills Lab - Bethlehem, PA
6/2/2017 » 6/3/2017
Intensive Anatomy and Hands-On Fluoroscopic Correlation - Biddeford, ME
6/23/2017 » 6/25/2017
Radiofrequency Bio-Skills Lab - Memphis, TN